Overwhelmingly positive results of Mast Therapeutics, Inc.‘s Phase 2 clinical trial of AIR001 (sodium nitrite, or Aironite®) inhalation solution for pulmonary arterial hypertension will lead to the company’s pursuit of additional Phase 2 trials in the near future. All doses of AIR001 were well-tolerated by patients and provided improvements…
News
Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress. Riociguat is the first member of…
When Gilead Sciences, Inc. initiated a clinical trial for first-line combination therapy for pulmonary arterial hypertension treatment, the company felt that their ambitious approach to developing a new, viable therapy for the disease was worthy of the clinical trial name “AMBITION.” Now, according to a…
Photo Caption: “The Process is the product” – Pluristem’s 3D expansion technology allows for the production of different PLX cell products. Photo credit: Pluristem Therapeutics Inc. Haifa, Israel based Pluristem Therapeutics Inc. a drug developer specializing in placenta-based cell therapy products, has announced that licensee partner United Therapeutics…
Pulmonary hypertension occurs when there is an abnormal buildup of blood pressure pumped from the heart to the pulmonary vasculature, eventually causing the vessels in the lungs to constrict and lead to a reduction in blood oxygenation. At present, this deadly disease remains incurable, with a 68 percent chance…
Pulmonary hypertension is a condition caused by increased pressure in the pulmonary arteries. In advanced cases, its symptoms (shortness of breath, tiredness, chest pain) worsen and may limit all physical activity. Now, researchers from University of California, Los Angeles have developed a successful treatment to rescue advanced forms of…
Biopharm company, Insmed Incorporated, has announced that they will present their novel inhalation technologies for the treatment of orphan pulmonary diseases such as pulmonary arterial hypertension at the European Respiratory Society’s (ERS) International Congress 2014. Held between September 6th and 10th at the Internationales Congress Center München, in…
Idiopathic pulmonary fibrosis (IPF) is an uncommon, yet deadly respiratory disease, characterized by a progressive decline in pulmonary function caused by lung scarring — the cause of which remains unknown today. Patients diagnosed with IPF along with their significant others recently received the good news that they are finally…
The U.S. District Court for the District of New Jersey has ruled in United Therapeutics Corporation‘s favor in the company’s case against Sandoz, regarding United Therapeutics’ Remodulin product. First approved in the United States in May 2002, Remodulin is a prostacyclin vasodilator used for the treatment of pulmonary arterial…
The U.S. Food and Drug Administration has granted APD811, an investigational drug candidate internally developed by Arena Pharmaceuticals, orphan drug status. APD811 is an oral agonist of the prostacyclin (IP) receptor, which is designed for the treatment of vasospastic diseases, such as pulmonary arterial hypertension (PAH). “The FDA Office of…
Omentin, an adipocyte-derived cytokine, is a potential novel candidate to treat obesity-related cardiovascular disease. Dr. Kyosuke Kazama and colleagues from the School of Veterinary Medicine, Kitasato University, Japan, have shown for the first time that long term treatment for 14 days with omentin inhibits vascular structural remodeling and abnormal contractile…
The first results of AMBITION, a large pulmonary arterial hypertension clinical trial, will be presented this month at the European Respiratory Society (ERS) International Congress 2014, as part of the highlights of the meeting. AMBITION is a randomized, double blind, multi center Phase 4 clinical trial testing the efficacy…
